| 摘要 |
The present invention provides new amyloidogenesis inhibiting compounds of formula (I): in which R<SUB>1 </SUB>is a -NR<SUB>a</SUB>R<SUB>b </SUB>group, where R<SUB>a </SUB>and R<SUB>b</SUB>, independently, are a hydrogen atom or a C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl group; -OR<SUB>C </SUB>group, where R<SUB>C </SUB>is a hydrogen atom or a C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl group; a glycosyl; a C<SUB>1</SUB>-C<SUB>6 </SUB>polyhydroxyalkyl; or a -NH-CH(R<SUB>d</SUB>)-COOR<SUB>e </SUB>group, where R<SUB>d </SUB>is a side chain of one of the 20 natural alpha-amino acids in either of their two enantiomerically pure forms L or D, and R<SUB>e </SUB>is a hydrogen atom or a C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl group; and R<SUB>2 </SUB>is a hydrogen atom, a C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl group, a glycosyl; a C<SUB>1</SUB>-C<SUB>6 </SUB>polyhydroxyalkyl; -C(-O)-R<SUB>f </SUB>group, where R<SUB>f </SUB>is a C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl group; or a -CH<SUB>2</SUB>-COO-R<SUB>g </SUB>group, where R<SUB>g </SUB>is a hydrogen atom or a C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl group; and pharmaceutically acceptable salts thereof, which are useful in the treatment of neurodegenerative diseases, among others.
|
